anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Long-term animal studies have not been performed to evaluate the carcinogenic potential of betamethasone dipropionate.

In a 90-day repeat-dose toxicity study in rats, topical administration of betamethasone dipropionate spray formulation at dose concentrations of 0.05% and 0.1% (providing dose levels up to 0.5 mg/kg/day in males and 0.25 mg/kg/day in females) resulted in a toxicity profile consistent with long-term exposure to corticosteroids including reduced body weight gain, adrenal atrophy, and histological changes in bone marrow, thymus and spleen indicative of severe immune suppression. A no observable adverse effect level (NOAEL) could not be determined in this study. Although the clinical relevance of the findings in animals to humans is not clear, sustained glucocorticoid-related immune suppression may increase the risk of infection and possibly the risk of carcinogenesis.

Betamethasone was negative in the bacterial mutagenicity assay (Salmonella typhimurium and Escherichia coli), and in the mammalian cell mutagenicity assay (CHO/HGPRT). It was positive in the in vitro human lymphocyte chromosome aberration assay, and equivocal in the in vivo mouse bone marrow micronucleus assay.

Studies in rabbits, mice, and rats using intramuscular doses up to 1 mg/kg, 33 mg/kg, and 2 mg/kg, respectively, resulted in dose-related increases in fetal resorptions in rabbits and mice.
The study intervention is the application of a prescribed outpatient care model including a nurse teacher educational program and quality of life surveys for both subjects and caregivers. Induction therapy and medical follow up are performed without prophylactic admission to an inpatient facility. Subjects will also receive CPX-351 according to FDA approval, to subjects who meet medical and logistical criteria for study enrollment.
This is a two arm, multicenter, open label phase II trial in adult patients with recurrent supratentorial high-grade glioma. One arm (the "bevacizumab naïve" arm) will enroll patients who have not received prior bevacizumab therapy, and the other arm (the "post-bevacizumab" arm) will enroll patients who have experienced progression on bevacizumab.

All subjects will receive BIBF 1120 at 200mg orally, twice daily in cycles of 28 days. Subjects will come to the clinic on Day 1 of each cycle (or within 2 days prior) for blood and urine tests and a physical and neurologic exam. Bloods will also be checked within 2 days before or after Day 15 of Cycles 1 and 2. An additional blood sample will be taken on Days 1 and 8 of Cycle 1, at the start of every even-numbered cycle, and at the end of active study treatment. Subjects will have gadolinium-enhanced brain MRI scans performed with tumor measurements at screening, at the start of even-numbered cycles, and at the end of active study treatment(unless already obtained within 4 weeks of completing study treatment). 40 study subjects will have diffusion- and perfusion-weighted MRI at baseline, after 1 week on therapy (± 2 days), within 2 days prior to the start of every even-numbered cycle, and at the end of treatment (unless already obtained within 4 weeks of completing study treatment).
ABSTRACT OF THE DISCLOSURE The invention relates to 15-cycloaliphatic derivatives of 13,14-di-dehydro carboprostacyclins of formula (I)                 (I) wherein R is hydrogen or a C1-C6 alkyl group optionally substituted by a group    wherein each of R3 and R4 is, independently, hydrogen or C1-C6 alkyl, or R3 and R4, taken together with the nitrogen atom to which they are linked, form a pentatomic or hexatomic heteromonocyclic ring optionally containing a further heteroatom chosen from O and S; n is zero or an integer of 1 to 5; one of R1 and R2 is hydrogen or C1-C6 alkyl and the other is hydroxy; and B repre-sents:  a) a C4-C7 monocycloaliphatic group either unsubstituted or substituted by one or more substituents chosen from C1-C6 alkyl, C2-C6 alkenyl and C1-C6 alkylidene; b) norbornyl; or c) adamantyl, and the pharmaceutically or veterin-arily acceptable salts of the compounds of formula (1).  The invention also re-lates to pharmaceutically or veterinarily acceptable salts of compounds of for-mula I.  The compounds of formula (I) show high platelet antiaggregating and disaggregating activity in that they strongly inhibit, prevent and reverse blood platelet aggregation.  The compounds are therefore useful to inhibit platelet aggregation, to decrease adhesions, to prevent clot formation and to dissolve recently-formed clots.  The platelet anti-aggregating activity is also associat-ed with a relaxation of the coronary arteries, so the compounds can be useful in preventing and treating myocardial infarctions and, in general, in treating or preventing thromboses, in treating conditions like atherosclerosis,  arterio-sclerosis and, more generally, hyperlipidemia.  The compounds also exhibit a vasodilatory, i.e. hypotensive, effect, so they may be useful for treating syndromes caused by arterial hypertension.  They may also be used for treating obstructive pulmonary diseases such as, e.g. bronchial asthma.  Further, they display antiulcerogenic and antisecretory activity.
PURPOSE: Regarding surgical indications for carpal tunnel syndrome (CTS), the hypothesis that the recovery processes of subjective symptoms differ among pain, sensory, and motor symptoms and correlate with recovery in objective nerve conduction studies was examined in the present study.
METHODS: The global symptom score (GSS) is a method used to assess clinical outcomes and covers subjective symptoms, including pain (pain and nocturnal awakening), sensory (numbness and paresthesia), and motor (weakness/clumsiness) symptoms. The relationships between long-term changes in GSS and recovery in nerve conduction studies were investigated.
RESULTS: Forty patients (40 hands) were included (mean age 65 years; 80% female; 68% with moderate CTS: sensory nerve conduction velocity < 45 m/s and motor nerve distal latency > 4.5 ms). Pain and nocturnal awakening rapidly subsided within 1 month after surgery and did not recur in the long term (median 5.6 years). Paresthesia significantly decreased 3 months after surgery and in the long term thereafter. Weakness/clumsiness significantly decreased at 1 year. Sensory nerve distal latency, conduction velocity, and amplitude significantly improved 3 months and 1 year after surgery, and correlated with nocturnal awakening in the short term (3 months) in moderate CTS cases. The patient satisfaction rate was 91%.
CONCLUSION: Rapid recovery was observed in pain and nocturnal awakening, of which nocturnal awakening correlated with the recovery of sensory nerve conduction velocity. Patients with pain symptoms due to moderate CTS may benefit from surgical release.
The present disclosure relates to systems and methods for filtering electronic activities. The method includes identifying an electronic activity. The method includes parsing the electronic activity to identify one or more electronic accounts in the electronic activity. The method includes determining, responsive to parsing the electronic activity, that the electronic activity is associated with an electronic account of the one or more electronic accounts. The method includes selecting, based on the electronic account, one or more filtering policies associated with the data source provider to apply to the electronic activity. The method includes determining, by applying the selected one or more filtering policies to the electronic activity, to restrict the electronic activity from further processing based on the electronic activity satisfying at least one of the selected one or more filtering policies. The method includes restricting, the electronic activity from further processing.
PROBLEM TO BE SOLVED: To obtain a preventive and therapeutic agent for proliferative disease having excellent effect of suppressing epidermal growth factor receptor(EGF-R) tyrosine kinase activity by formulating sporostain. SOLUTION: This medicine contains a compound of the formula or its salt as an active ingredient. The compound of the formula is officially known compound M5032 substance (called sporostatin) and is obtained by culturing the fungus Sporormiella sp. M5032 in a medium. The compound formed and acculated in the cultured product is isolated from the cultured product and purified. This medicine is useful for treatment of malignant proliferative disases originating from epithelium, e.g. tumors such as mammary carcinoma, esphageal carcinoma, cystocarcinoma, ovarian cancer, vulvar cancer, colon cancer, pulmonary carcinoma, melanoma, mouth cancer and brain tumor, or benign proliferative diseases, e.g. psoriasis, pulmonary fibrosis and polycystic renal disease. It is orally and parenterally administrated at a dose of 0.05-10mg/kg/day/adult.
OBJECTIVE: Levodopa-induced dyskinesia (DYS) adversely affects the quality of life of Parkinson's disease (PD) patients. However, few studies have focused on the relationship between DYS and sleep and electroencephalography (EEG). Our study aimed to establish the objective physiological indicators assessed by polysomnography (PSG) that are associated with DYS in PD patients.
METHODS: We enrolled 122 patients with PD, divided into two groups: PD with DYS (n = 27) and PD without DYS group (non-DYS, n = 95). The demographics and clinical characteristics and sleep assessment in the two groups were collected. More importantly, overnight six-channel PSG parameters were compared in the two groups. We also compared different bands and brain regions of average power spectral density within each group.
RESULTS: Compared with the non-DYS group, the DYS group tended to have a significantly higher percentage of nonrapid eye movement sleep (NREM). Gender, levodopa equivalent daily dose (LEDD), rapid eye movement (REM) sleep (min), and the NREM percentage were positively correlated with the occurrence of DYS. After adjusting for gender, disease duration, LEDD, taking amantadine or not, and Montreal Cognitive Assessment (MoCA), NREM%, N3%, and REM (min), the percentage of NREM sleep (p = 0.035), female (p = 0.002), and LEDD (p = 0.005), and REM sleep time (min) (p = 0.012) were still associated with DYS. There was no significant difference in whole-night different bands of average power spectral density between two groups. There was no significant difference in normalized average power spectral density of slow wave activity (SWA) (0.5-2 Hz, 0.5-4 Hz, and 2-4 Hz) of early and late NREM sleep in the DYS group. Dynamic normalized average power spectral density of SWA of low-frequency (0.5-2 Hz) reduction in the frontal region (p = 0.013) was associated with DYS in logistic regression after adjusting for confounding factors.
CONCLUSION: PD patients with DYS have substantial sleep structure variations. Higher NREM percentage and less REM percentage were observed in PD patients with DYS. Dynamic normalized average power spectral density of low-frequency (0.5-2 Hz) SWA reduction in the frontal area could be a new electrophysiological marker of DYS in PD.
1326080 Non-woven fabric containing microcapsules CARL FREUDENBERG 26 Oct 1970 [5 Nov 1969] 50784/70 Headings D1R D2A and D2B [Also in Division A5] A non-woven fibrous material has microcapsules distributed throughout a central portion only of its thickness. The microcapsules may be filled with a 'freshening aid, e.g. a perfume. The fibrous material may be natural or synthetic, e.g. viscose rayon, polyester. The material may be made by a conventional air laying method, or by wet laying in superimposing manner a fibrous suspension, then an aqueous dispersion of microcapsules, and finally a fibrous suspension similar to the first fibrous suspension. The aqueous dispersion of microcapsules may contain fibres and the fibrous suspenions may contain a binder, e.g. butadiene-styrene latex which may be coagulated by addition of alum. Paper-making apparatus. This comprises a continuous screen 4 movable around rollers 12-15, ducts 1, 2, 3, through which materials to be wet laid are supplied to the screen, and suction box 11. A plate 10 may be positioned above the screen to reduce turbulence.
Administered IV as a single dose over 30 minutes on the morning of Day 1 following an 8 hour overnight fast and remain in the clinical unit until up to 168 hours after dosing (to Day 8). If mass balance criteria have not been met on Day 8, the clinical unit residency may be extended up to an additional 96 hours (to Day 12).
The invention discloses unprocessed rehmannia root chrysanthemum liquor which is prepared through conventional technologies from following components, by weight, 50 parts of unprocessed rehmannia root, 20 parts of chrysanthemum, 40 parts of angelica sinensis, 20 parts of fructus lycii, 80 parts of rock candy, 20 parts of rhizoma atractylodis, 20 parts of poria cocos, 15 parts of morinda officinalis, 20 parts of semen plantaginis and 1000 parts of liquor. The components, except the liquor, are placed in a container with addition of the liquor. The container is sealed and the components are soaked in the liquor for 15 days. Filtration is carried out to remove residues to obtain the unprocessed rehmannia root chrysanthemum liquor. The unprocessed rehmannia root chrysanthemum liquor has effects of tonifying liver and kidney and boosting yin blood, is mainly used for treating deficiency of essence and blood and withered appearance in elder people. The unprocessed rehmannia root chrysanthemum liquor is taken orally with a dosage being 10-20ml by two times per day.
The patients randomized PAP will receive a PAP prescription and a physical activity diary. The PAP and physical activity diary will be followed up at 6 and 12 weeks after the inclusion.
The invention relates to a worm grass and Chinese blister beetle composition, an enteric preparation, and an application and a preparation thereof. The composition mainly comprises the materials in part by weight as follows: 5-20 parts of cordyceps sinensis, 0.1-10 parts of sodium cantharidate and 5-15 parts of vitamin B6. The enteric preparation comprises a chip and an enteric coating. The composition and auxiliary materials are prepared into the chip and enteric coating to obtain the enteric preparation. The worm grass and Chinese blister beetle composition and the enteric preparation prepared treat cancers and improve immunity, and have good curative effect in treatment of various cancers such as cancer of the liver, lung cancer and ovarian cancer and the like. The enteric preparation releases medicines in the intestinal tract, avoids stomach irritation and toxicity, and improves the absorptivity.
INTRODUCTION: Traditional Chinese medicinal plant, safflower, shows effective for treating pulmonary arterial hypertension (PAH), yet the underlying mechanisms remain largely unexplored. This study is aimed at exploring the potential molecular mechanisms of safflower in the treatment of PAH.
METHODS: Network pharmacology approach and molecular docking were applied to identify the core active compounds, therapeutic targets, and potential signaling pathways of safflower against PAH. Meanwhile, high-performance liquid chromatography (HPLC) assay was performed to determine the core compounds from safflower. Further, the mechanism of action of safflower on PAH was verified by in vivo and in vitro experiments.
RESULTS: A total of 15 active compounds and 177 targets were screened from safflower against PAH. Enrichment analysis indicated that these therapeutic targets were mainly involved in multiple key pathways, such as TNF signaling pathway and Th17 cell differentiation. Notably, molecular docking revealed that quercetin (core compound in safflower) displayed highest binding capacity with NLRP3. In vivo, safflower exerted therapeutic effects on PAH by inhibiting right ventricular hypertrophy, inflammatory factor release, and pulmonary vascular remodeling. Mechanistically, it significantly reduced the expression of proangiogenesis-related factors (MMP-2, MMP-9, Collagen 1, and Collagen 3) and NLRP3 inflammasome components (NLRP3, ASC, and Caspase-1) in PAH model. Similarly, these results were observed in vitro. Besides, we further confirmed that NLRP3 inhibitor had the same therapeutic effect as safflower in vitro.
CONCLUSION: Our findings suggest that safflower mitigates PAH primarily by inhibiting NLRP3 inflammasome activation. This provides novel insights into the potential use of safflower as an alternative therapeutic approach for PAH.
Treatment on this protocol requires placement of 3-5 gold (99.9% pure, 1-5 mm length, or visicoils) fiducials for targeting purposes. The fiducials will be used as surrogates for targeting the daily tumor position during treatment. The fiducials will be placed directly into the tumor and/or periphery under endoscopic ultrasound or CT guidance. Gemcitabine prior to SBRT is optional. If given, up to 3 weeks in a 6-week period is allowable, and may be given prior to study enrollment. Administration should be on a 3-week on, 1-week off schedule, weekly at 1,000 mg/m2. Simulation should be done 5 days or more following placement of fiducials. For simulation patients will be positioned supine in an Alpha Cradle or equivalent immobilization device will be custom made for each patient. Standard free-breathing CT and respiratory-correlated 4-D pancreatic protocol CT will be obtained on each patient The 4D-CT scan will be used for characterizing target motion during quiet respiration. Following simulation, patients may be treated either in a respiratory gated (Trilogy, Elekta, Novalis) or a respiratory tracking (Cyberknife) manner. The selection of which radiotherapy treatment machine to use is left to each investigator. All patients will receive 5 fractions of 6.6 Gy delivered over a five-day period. Ideally all 5 fractions should be delivered Monday through Friday, however it may be delivered over 2 weeks as long as the patient receives at least 2 fractions a week. Gemcitabine, cycles should resume up to 4 weeks following SBRT on a 3-week on, 1-week off schedule, administered weekly at 1,000 mg/m2.A detailed medical history with physical examination and quality of life assessment will be performed at 4 months, 6 months, 9 months and 1 year. A follow-up visit at 4 weeks is optional and may be done by patient's Medical Oncologist. Scans may be done at 4-6 week visit if patient is being re-evaluated for resection.

In years 2-5 the follow up interval will be every 3-6 months, as determined by the investigator at each participating institution. Follow up intervals may also be more frequent as indicated clinically. A complete blood count (CBC), comprehensive chemistry panel, tumor marker studies, and quality of life assessment will be performed at each follow-up interval until death. As permitted by each participating institution, separate samples of blood will be drawn and retained for research efforts to develop novel serum biomarkers.
All patients will obtain an 18F-Fluciclovine PET/CT scan in addition to the planning MRI at the time of SRS treatment (approximately 2-4 weeks after resection). The value of 18F-Fluciclovine in addition to structural information from the MRI will be analyzed. Patients will continue to undergo 18F-Fluciclovine in addition to MRI during routine follow-up to determine the ability of 18F-Fluciclovine PET/CT to identify areas at risk for marginal failure, monitor resection beds for tumor control, identify patients at risk for disease recurrence, and detect patterns of failure.
In this study, to address the defects of sodium alginate (SA), such as its susceptibility to disintegration, silica was coated on the outer layer of sodium alginate hydrogel beads in order to improve its swelling and slow-release properties. Tetraethyl orthosilicate (TEOS) was used as the hydrolyzed precursor, and the solution of silica precursor was prepared by sol-gel reaction under acidic conditions. Then SA-silica hydrogel beads prepared by ionic crosslinking method were immersed into the SiO2 precursor solution to prepare SA-silica hydrogel beads. The chemical structure and morphology of the hydrogel beads were characterized by XRD, FTIR, and SEM, and the results showed that the surface of SA-silica beads was successfully encapsulated with the outer layer of SiO2, and the surface was smooth and dense. The swelling experiments showed that the swelling performance effectively decreased with the increase of TEOS molar concentration, and the maximum swelling ratio of the hydrogel beads decreased from 41.07 to 14.3, and the time to reach the maximum swelling ratio was prolonged from 4 h to 8 h. The sustained-release experiments showed that the SA-silica hydrogel beads possessed a good pH sensitivity, and the time of sustained-release was significantly prolonged in vitro. Hemolysis and cytotoxicity experiments showed that the SA-silica hydrogel beads were biocompatible when the TEOS molar concentration was lower than 0.375 M. The SA-silica-2 hydrogel beads had good biocompatibility, swelling properties, and slow-release properties at the same time.
An apparatus is provided for maintaining control of a machine which produces thrust, rotation or other outputs in response to input signals. The apparatus has two distinct parts, namely the operator input portion and the output portion. The operator input portion consists of the primary thrust, rotation and other output control, and the input signal generation, signal maintenance and signal resume control. Through these controls, the operator enters the desired operation at conditions and levels for rotation, thrust, and other input signals. The output portion consists of an information processing and control portion and the power units for rotation, thrust and other outputs generated from the machine. The information processing and control system interprets all of the desired operational conditions and levels from the input portion and sends commands to the thrust, rotation and other power units to produce the desired outputs in response to the input signals.
Introduction: Sarcomatoid differentiation has been reported in approximately 8% of chromophobe renal cell carcinoma (RCC) and is associated with a worse prognosis. We aim to describe the clinicopathologic and molecular findings of chromophobe RCC with sarcomatoid differentiation. Methods: Surgical pathology database was searched to identify chromophobe RCC with sarcomatoid differentiation from January 2015 to December 2021. Results: Five patients were diagnosed with chromophobe RCC with sarcomatoid differentiation. The median age at the time of diagnosis was 57 years (range 51-61 years). Three patients died after median follow-up of 12.1 months (range 1.6-18.2 months). The median tumor size was 10.7 cm (range 5.6-13.6 cm). The median percentage of sarcomatoid component was 60% (range 10-90%), and the median percentage of necrosis was 30% (range 10-50%). One tumor demonstrated osteoid formation. PAX8, keratin 7, KIT (CD117), and Hale colloidal iron were positive in the epithelial component, whereas the sarcomatoid component was positive for vimentin, CD10, and high Ki67 proliferative index. Molecular testing was performed in three specimens: all were TP53 mutated and microsatellite stable. One aggressive tumor had RB1 frameshift mutation and copy number gains for TERT and CUL4A. Conclusion: Chromophobe RCC with sarcomatoid differentiation is a rare entity with aggressive behavior. Percentage of sarcomatoid component, necrosis, and the occurrence of metastasis is associated with worse prognosis. Molecular profiling reveals frequent TP53 mutation. While TERT promoter mutation has no prognostic implication, FLCN inactivation may be associated with a less aggressive course. The clinical significance of RB1 loss is unclear.